Zi-Wei Ye

Dr. Zi-Wei Ye

orcid

Research Focus & Metrics

Academic Career Length

8Years (2019-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 June 2020 in Viruses
Verified
Journal Article
Open access
PDF file
Shuofeng YuanShuofeng Yuan
Shuofeng Yuan
CCChris Chun Yiu Chan
Chris Chun Yiu Chan
KCKenn Ka-Heng Chik
Kenn Ka-Heng Chik
JTJessica Oi-Ling Tsang
Jessica Oi-Ling Tsang
RLRonghui Liang
Ronghui Liang
Jasper Fuk Woo ChanJasper Fuk Woo Chan
Jasper Fuk Woo Chan
The ongoing Coronavirus Disease 2019 (COVID-19) pandemic caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) signals an urgent need for an expansion in treatment options. In this study, we investigated the anti-SARS-CoV-2 activities of 22 antiviral agents with known broad-spectrum antiviral activities against coronaviruses and/or other viruses. They were first evaluated in our primary screening in VeroE6 cells and then the most potent anti-SARS-CoV-2 antiviral agents were further evaluated using viral antigen expression, viral load reduction, and plaque reduction assays. In addition to remdesivir, lopinavir, and chloroquine, our primary screening additionally identified types I and II recombinant interferons, 25-hydroxycholesterol, and AM580 as the most potent anti-SARS-CoV-2 agents among the 22 antiviral agents. Betaferon (interferon-β1b) exhibited the most potent anti-SARS-CoV-2 activity in viral antigen expression, viral load reduction, and plaque reduction assays among the recombinant interferons. The lipogenesis modulators 25-hydroxycholesterol and AM580 exhibited EC50 at low micromolar levels and selectivity indices of >10.0. Combinational use of these host-based antiviral agents with virus-based antivirals to target different processes of the SARS-CoV-2 replication cycle should be evaluated in animal models and/or clinical trials.

25 April 2019 in Viruses
Verified
Journal Article
Open access
PDF file
Shuofeng YuanShuofeng Yuan
Shuofeng Yuan
Jasper Fuk Woo ChanJasper Fuk Woo Chan
Jasper Fuk Woo Chan
ZYZi-Wei Ye
Zi-Wei Ye
LWLei Wen
Lei Wen
TTTerance Gi-Wai Tsang
Terance Gi-Wai Tsang
KYKwok-Yung Yuen
Kwok-Yung Yuen
Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging tick-borne bunyavirus that causes severe disease in humans with case-fatality rates of up to 30%. There are currently very limited treatment options for SFTSV infection. We conducted a drug repurposing program by establishing a two-tier test system to rapidly screen a Food and Drug Administration- (FDA)-approved drug library for drug compounds with anti-SFTSV activity in vitro. We identified five drug compounds that inhibited SFTSV replication at low micromolar concentrations, including hexachlorophene, triclosan, regorafenib, eltrombopag, and broxyquinoline. Among them, hexachlorophene was the most potent with an IC50 of 1.3 ± 0.3 µM and a selectivity index of 18.7. Mechanistic studies suggested that hexachlorophene was a virus entry inhibitor, which impaired SFTSV entry into host cells by interfering with cell membrane fusion. Molecular docking analysis predicted that the binding of hexachlorophene with the hydrophobic pocket between domain I and domain III of the SFTSV Gc glycoprotein was highly stable. The novel antiviral activity and mechanism of hexachlorophene in this study would facilitate the use of hexachlorophene as a lead compound to develop more entry inhibitors with higher anti-SFTSV potency and lower toxicity.

27 August 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
BHBodan Hu
Bodan Hu
KCKenn Ka-Heng Chik
Kenn Ka-Heng Chik
Jasper Fuk Woo ChanJasper Fuk Woo Chan
Jasper Fuk Woo Chan
JCJianpiao Cai
Jianpiao Cai
HCHehe Cao
Hehe Cao
Shuofeng YuanShuofeng Yuan
Shuofeng Yuan
Enterovirus A71 (EV-A71) infection is a major cause of hand, foot, and mouth disease (HFMD), which may be occasionally associated with severe neurological complications. There is currently a lack of treatment options for EV-A71 infection. The Raf-MEK-ERK signaling pathway, in addition to its critical importance in the regulation of cell growth, differentiation, and survival, has been shown to be essential for virus replication. In this study, we investigated the anti-EV-A71 activity of vemurafenib, a clinically approved B-Raf inhibitor used in the treatment of late-stage melanoma. Vemurafenib exhibits potent anti-EV-A71 effect in cytopathic effect inhibition and viral load reduction assays, with half maximal effective concentration (EC50) at nanomolar concentrations. Mechanistically, vemurafenib interrupts both EV-A71 genome replication and assembly. These findings expand the list of potential antiviral candidates of anti-EV-A71 therapeutics.

11 October 2021 in Viruses
Verified
Journal Article
Open access
PDF file
Shuofeng YuanShuofeng Yuan
Shuofeng Yuan
LWLei Wen
Lei Wen
KCKenn Ka-Heng Chik
Kenn Ka-Heng Chik
JDJiang Du
Jiang Du
ZYZi-Wei Ye
Zi-Wei Ye
Jasper Fuk Woo ChanJasper Fuk Woo Chan
Jasper Fuk Woo Chan
Severe fever with thrombocytopenia syndrome virus (SFTSV) is an emerging tick-borne bunyavirus in Asia that causes severe disease. Despite its clinical importance, treatment options for SFTSV infection remains limited. The SFTSV glycoprotein Gn plays a major role in mediating virus entry into host cells and is therefore a potential antiviral target. In this study, we employed an in silico structure-based strategy to design novel cyclic antiviral peptides that target the SFTSV glycoprotein Gn. Among the cyclic peptides, HKU-P1 potently neutralizes the SFTSV virion. Combinatorial treatment with HKU-P1 and the broad-spectrum viral RNA-dependent RNA polymerase inhibitor favipiravir exhibited synergistic antiviral effects in vitro. The in silico peptide design platform in this study may facilitate the generation of novel antiviral peptides for other emerging viruses.

20 November 2023 in npj Vaccines
Verified
Journal Article
Open access
PDF file
COChon Phin Ong
Chon Phin Ong
KTKaiming Tang
Kaiming Tang
PCPak-Hin Hinson Cheung
Pak-Hin Hinson Cheung
HZHongzhuo Zhang
Hongzhuo Zhang
TTTze-Tung Tang
Tze-Tung Tang
Dong-Yan JinDong-Yan Jin
Dong-Yan Jin
We compared the protective effects of inactivated SARS-CoV-2 vaccines derived from the ancestral and the currently circulating BA.5.2 strains against infection with multiple variants in Syrian golden hamsters. Vaccination with BA.5.2 effectively protected against infection with the Omicron subvariants including XBB.1, but not the Alpha or Delta variant. In contrast, hamsters vaccinated with the ancestral strain demonstrated decent neutralization activity against both the Omicron and non-Omicron variants. Our findings might instruct future design and formulation of SARS-CoV-2 vaccines.

8 September 2025 in PLOS Pathogens
Verified
Journal Article
Open access
PDF file
CWChenxi Wang
Chenxi Wang
YXYubin Xie
Yubin Xie
WLWeixin Li
Weixin Li
COChon Phin Ong
Chon Phin Ong
HDHao Ding
Hao Ding
ZYZi-Wei Ye
Zi-Wei Ye
Zika virus (ZIKV) has emerged as a rising concern in global health in recent years. The role of PD-1/PD-L1 immune checkpoint in acute ZIKV infection remains to be understood. In this study we demonstrated the activation of PD-1/PD-L1 immune checkpoint by ZIKV. mRNA and protein expression of PD-L1 was boosted by ZIKV not only in SF268 and JEG3 cell lines but also in human dendritic cells. PD-1 expression was more abundant on CD8+ T cells in ZIKV-infected mice. Elevated PD-L1 expression was also observed in the brain, testis and spleen of ZIKV-infected A129 mice. Blocking PD-L1 effectively inhibited ZIKV infection, reducing viral loads in all tissues. In addition, anti-PD-L1 antibody treatment further increased virus-specific CD8+ T cells, KLRG+ CD8+ T cells, and effector memory CD8+ T cells. PD-L1 blockade also induced interferon γ, granzyme B, and interleukin 2 expression in antigen-specific CD8+ T cells, consistent with activation of these cells. Mechanistically, the induction of PD-L1 expression might be ascribed to viral NS4B protein and its interaction with GRP78. Our findings suggest that targeting the PD-1/PD-L1 pathway could have antiviral effect against ZIKV.